Eli Lilly and Company $LLY Shares Acquired by Clark Capital Management Group Inc.

Key Points

• Clark Capital Management Group Inc. increased its holdings in Eli Lilly by 19.0%, acquiring an additional 21,128 shares, bringing its total to 132,369 shares worth approximately $109 million.
• Eli Lilly reported strong quarterly earnings with a EPS of $6.31, exceeding analysts' estimates, and revenue of $15.56 billion, a 37.6% increase year-over-year.
• The company declared a quarterly dividend of $1.50, resulting in an annualized dividend yield of 0.8%, with a dividend payout ratio of 39.22%.

Clark Capital Management Group Inc. grew its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 19.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 132,369 shares of the company's stock after acquiring an additional 21,128 shares during the quarter. Eli Lilly and Company comprises about 0.8% of Clark Capital Management Group Inc.'s portfolio, making the stock its 28th biggest position. Clark Capital Management Group Inc.'s holdings in Eli Lilly and Company were worth $109,325,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Corient IA LLC purchased a new position in Eli Lilly and Company during the 1st quarter worth $570,000. LS Investment Advisors LLC grew its stake in Eli Lilly and Company by 1.7% during the 1st quarter. LS Investment Advisors LLC now owns 2,340 shares of the company's stock worth $1,933,000 after buying an additional 40 shares during the last quarter. Cutter Capital Management LP purchased a new position in Eli Lilly and Company during the 1st quarter worth $14,866,000. Prism Advisors Inc. purchased a new position in Eli Lilly and Company during the 1st quarter worth $207,000. Finally, Hemington Wealth Management grew its stake in Eli Lilly and Company by 14.4% during the 1st quarter. Hemington Wealth Management now owns 985 shares of the company's stock worth $813,000 after buying an additional 124 shares during the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on LLY. Hsbc Global Res upgraded Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a research note on Wednesday, August 27th. Guggenheim dropped their target price on Eli Lilly and Company from $942.00 to $875.00 and set a "buy" rating on the stock in a research note on Wednesday, August 13th. UBS Group dropped their target price on Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating on the stock in a research note on Friday, August 8th. Daiwa America downgraded Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research note on Sunday, August 17th. Finally, Daiwa Capital Markets downgraded Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 price target on the stock. in a research note on Sunday, August 17th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and eight have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $950.17.

Insider Buying and Selling

In other Eli Lilly and Company news, Director Jamere Jackson purchased 200 shares of Eli Lilly and Company stock in a transaction that occurred on Friday, August 8th. The stock was bought at an average price of $639.56 per share, with a total value of $127,912.00. Following the acquisition, the director owned 9,402 shares of the company's stock, valued at $6,013,143.12. This trade represents a 2.17% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO David A. Ricks purchased 1,632 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The stock was acquired at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the acquisition, the chief executive officer directly owned 546,601 shares in the company, valued at $352,431,926.77. This trade represents a 0.30% increase in their position. The disclosure for this purchase can be found here. Insiders have acquired a total of 4,514 shares of company stock worth $2,894,841 in the last ninety days. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock traded down $16.56 during trading hours on Friday, hitting $726.35. 3,953,474 shares of the stock traded hands, compared to its average volume of 5,282,453. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The firm's 50 day moving average price is $743.84 and its 200-day moving average price is $781.22. The stock has a market capitalization of $687.46 billion, a price-to-earnings ratio of 47.47, a P/E/G ratio of 1.01 and a beta of 0.47. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $942.35.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating the consensus estimate of $5.59 by $0.72. The business had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company's quarterly revenue was up 37.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, equities analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be issued a $1.50 dividend. This represents a $6.00 annualized dividend and a dividend yield of 0.8%. The ex-dividend date of this dividend is Friday, August 15th. Eli Lilly and Company's payout ratio is 39.22%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.